Twenty-seven evaluable patients with small cell lung cancer (SCLC) resistant to, or relapsed
after induction combination chemotherapy (CT) were treated with etoposide (VPJ6) plus …

BACKGROUND In an attempt to determine the efficacy of cyclophosphamide, doxorubicin,
and vincristine (CAV)/cisplatin and etoposide (PVP) hybrid chemotherapy (HYB), a rapidly …

Small cell carcinoma of the lung (SCCL) responds commonly to combination chemotherapy
but resistance to therapy follows. Prior reports have suggested that a relationship may exist …

Introduction Small-cell lung cancer (SCLC) is a highly vascularized tumor. ASA404 is a
tumor vascular disrupting agent. This is the first trial to report the effects of combining …

The aim of this prospective study was to assess the activity of a combination of vincristine,
epirubicin and cyclosphosphamide (VEC) in previously untreated patients with limited small …

We have treated sixty-two patients (21 with limited disease, 41 with extensive disease), on
an outpatient-basis schedule of six drugs administered weekly for twelve weeks …

Abstract 17 previously untreated patients with small cell lung cancer entered a phase II study
testing the feasibility of incorporating high dose epirubicin (110 mg/m2, day 1) in …

BACKGROUND Information on the effect of chemotherapy in a group of patients with poor
prognosis, poor performance status small cell lung carcinoma (SCLC) is scarce. A …

Fifty‐four patients with small cell cancer of the lung (SCCL) who failed to respond to
induction chemotherapy or relapsed within 3 months of its completion were treated either …

A total of 353 patients with previously untreated small-cell lung cancer (SCLC) were accrued
in this multicenter trial. Patients were randomly assigned to receive one of the following …